LifeVantage Co. (NASDAQ:LFVN) Director Raymond B. Greer Sells 8,000 Shares

LifeVantage Co. (NASDAQ:LFVN) Director Raymond B. Greer sold 8,000 shares of LifeVantage stock in a transaction on Monday, February 10th. The stock was sold at an average price of $20.15, for a total transaction of $161,200.00. Following the sale, the director now directly owns 99,288 shares of the company’s stock, valued at $2,000,653.20. This represents a 7.46 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

LifeVantage Stock Performance

Shares of LifeVantage stock traded down $0.32 on Wednesday, reaching $19.36. 349,800 shares of the stock were exchanged, compared to its average volume of 322,604. The firm’s 50 day moving average is $19.53 and its 200-day moving average is $14.06. LifeVantage Co. has a one year low of $5.22 and a one year high of $27.38. The firm has a market cap of $242.97 million, a PE ratio of 34.57 and a beta of 0.84.

LifeVantage (NASDAQ:LFVN) last issued its earnings results on Wednesday, February 5th. The company reported $0.22 earnings per share for the quarter, beating analysts’ consensus estimates of $0.14 by $0.08. LifeVantage had a net margin of 3.46% and a return on equity of 34.29%.

LifeVantage Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, March 17th. Shareholders of record on Monday, March 3rd will be paid a $0.04 dividend. This represents a $0.16 annualized dividend and a yield of 0.83%. The ex-dividend date of this dividend is Monday, March 3rd. LifeVantage’s dividend payout ratio (DPR) is currently 28.57%.

Analyst Ratings Changes

Several research firms recently commented on LFVN. Craig Hallum began coverage on shares of LifeVantage in a research report on Tuesday, January 14th. They issued a “buy” rating and a $35.00 price objective on the stock. Lake Street Capital started coverage on shares of LifeVantage in a research note on Thursday, December 19th. They set a “buy” rating and a $26.00 price objective on the stock.

Institutional Investors Weigh In On LifeVantage

Several hedge funds and other institutional investors have recently bought and sold shares of LFVN. Copeland Capital Management LLC purchased a new position in LifeVantage during the fourth quarter worth about $65,000. Hillsdale Investment Management Inc. boosted its stake in LifeVantage by 7.3% in the fourth quarter. Hillsdale Investment Management Inc. now owns 14,720 shares of the company’s stock valued at $258,000 after acquiring an additional 1,000 shares during the last quarter. Ritholtz Wealth Management raised its position in shares of LifeVantage by 62.0% in the third quarter. Ritholtz Wealth Management now owns 28,666 shares of the company’s stock valued at $346,000 after purchasing an additional 10,974 shares during the period. Barclays PLC raised its position in shares of LifeVantage by 38.2% in the third quarter. Barclays PLC now owns 41,966 shares of the company’s stock valued at $507,000 after purchasing an additional 11,608 shares during the period. Finally, HighTower Advisors LLC bought a new stake in LifeVantage during the 3rd quarter worth approximately $638,000. 35.32% of the stock is owned by institutional investors.

About LifeVantage

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.